Clinical Trial

Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

Study acronym: OPTIMUS-EL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-02; most recent amendment 2025-11-25.
Status change: Not Yet Recruiting → Recruiting 2025-11-25
Trial Details
NCT Number NCT06920251
Lead Sponsor Seoul National University Hospital
Conditions Relapsed Refractory Multiple Myeloma (RRMM)
Enrollment 40 participants
Start Date 2025-09-11
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-03